Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Breast Neoplasms 1

Interventions

ruxolitinib 7givinostat hydrochloride 3givinostat 3anagrelide 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3bomedemstat 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2LY2784544 2spartalizumab 1sonidegib 1sabatolimab 1navitoclax 1lestaurtinib 1imetelstat 1ON 01910 1NIS-793 1N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1INCB057643 1Fentanyl 1Diagnosis 1Decitabine 1Celecoxib 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thrombocythemia, Essential × Diagnosis × Clear all
NCT03121599 2020-08-11

18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Hamad Medical Corporation

Phase NA Terminated
3 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡